HC Wainwright Brokers Reduce Earnings Estimates for Harrow

Harrow, Inc. (NASDAQ:HROW) – Analysts at HC Wainwright reduced their Q3 2026 EPS estimates for shares of Harrow in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $0.01 per share for the quarter, down from their prior forecast of $0.26. The consensus estimate for Harrow’s current full-year earnings is $0.30 per share. HC Wainwright also issued estimates for Harrow’s FY2026 earnings at ($0.57) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.12) EPS and FY2027 earnings at $0.88 EPS.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, August 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.28). Harrow had a negative net margin of 13.51% and a negative return on equity of 31.83%. The business had revenue of $70.66 million during the quarter, compared to analyst estimates of $70.35 million.

A number of other analysts also recently weighed in on the stock. Cantor Fitzgerald reduced their price target on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research note on Monday, July 20th. Wall Street Zen lowered Harrow from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $63.00 price target on shares of Harrow in a report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $69.43.

Harrow Trading Down 1.2%

Shares of Harrow stock opened at $38.87 on Friday. Harrow has a 1 year low of $28.54 and a 1 year high of $54.85. The company’s fifty day simple moving average is $40.81 and its 200-day simple moving average is $39.88. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -38.87 and a beta of 0.28. The company has a current ratio of 2.48, a quick ratio of 2.30 and a debt-to-equity ratio of 10.30.

Insider Transactions at Harrow

In related news, Director Adrienne L. Graves bought 1,000 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was acquired at an average cost of $31.07 per share, with a total value of $31,070.00. Following the acquisition, the director owned 1,000 shares in the company, valued at approximately $31,070. This represents a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 12.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Harrow

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Harrow in the second quarter worth $116,373,000. Vanguard Group Inc. lifted its position in Harrow by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock worth $94,162,000 after buying an additional 50,889 shares in the last quarter. Luxor Capital Group LP grew its holdings in Harrow by 22.0% during the 1st quarter. Luxor Capital Group LP now owns 1,119,400 shares of the company’s stock worth $39,470,000 after acquiring an additional 201,859 shares during the last quarter. Geode Capital Management LLC grew its holdings in Harrow by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 785,089 shares of the company’s stock worth $38,477,000 after acquiring an additional 9,445 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Harrow by 56.4% during the first quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock worth $20,428,000 after purchasing an additional 208,972 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: HC Wainwright reaffirmed its longer-term outlook for Harrow by projecting $1.07 in fourth-quarter 2027 EPS, slightly above its previous $1.06 estimate. The firm also expects Harrow to reach $0.88 in full-year 2027 EPS, despite lowering that estimate from $1.14. HC Wainwright estimates
• Positive Sentiment: A Seeking Alpha analysis characterized Harrow’s second-quarter performance as a potential turnaround and rated the shares a cautious buy, suggesting that improving operations could support future growth. Harrow: The Q2 Turnaround Is Enough For A Cautious Buy
• Positive Sentiment: BTIG Research reaffirmed its Buy rating, while coverage highlighted Harrow’s new eye-care product launch and acquisition as potential sources of additional growth. BTIG Research Reaffirms Buy Rating
• Neutral Sentiment: Viatris’ planned sale of Tyrvaya could create an opportunity for Harrow to expand the product into a larger growth engine, though the investment case depends on execution and commercial adoption. Tyrvaya growth opportunity
• Negative Sentiment: HC Wainwright sharply reduced its forecasts: FY2026 EPS moved from $0.15 to a loss of $0.57, Q3 2026 EPS from $0.26 to $0.01, Q1 2027 EPS from a $0.43 loss to a $0.63 loss, and Q2 2027 EPS from a $0.03 loss to a $0.12 loss. Zacks Research also downgraded Harrow from “Hold” to “Strong Sell.” Zacks downgrade
• Negative Sentiment: The stock gapped down following quarterly results in which Harrow reported a $0.46 per-share loss, missing the $0.18 consensus estimate, although revenue of $70.66 million modestly exceeded expectations. Harrow shares gap down following weak earnings

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.